Cognition enhancers between treating and doping the mind

Pharmacological Research

Volumn 57, Issue 3, 2008, Pages 196-213

  Lanni, Cristina ^a   Lenzken, Silvia C ^a   Pascale, Alessia ^a   Del Vecchio, Igor ^a   Racchi, Marco ^a   Pistoia, Francesca ^a   Govoni, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Attention; Cognitive enhancers; Creativity; Memory; Neuroinformatics

Indexed keywords

ADENOSINE; ANIRACETAM; ATOMOXETINE; CAFFEINE; CANNABIS; DIGITALIS; DONEPEZIL; DOPAMINE; ESCITALOPRAM; GALANTAMINE; GLUTAMIC ACID; HALOPERIDOL; ISPRONICLINE; LYSERGIDE; MEM 3454; MEM 63908; MEMANTINE; MESCALINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE; NICOTINE; NICOTINIC AGENT; NOOTROPIC AGENT; OXIRACETAM; PIRACETAM; PSILOCYBINE; RIVASTIGMINE; ROPINIROLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ALZHEIMER DISEASE; ART; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CREATIVITY; DRUG ABUSE; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MEDICAL ETHICS; MEMORY; MENTAL PERFORMANCE; NARCOLEPSY; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ATTENTION; BRAIN; COGNITION; COMPUTATIONAL BIOLOGY; HUMANS; MEMORY; MENTAL DISORDERS; MENTAL PROCESSES; NOOTROPIC AGENTS; SUBSTANCE-RELATED DISORDERS;

EID: 41549123496     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.02.004     Document Type: Review

References (181)

1. Amadio M., Govoni S., Alkon D.L., and Pascale A. Emerging targets for the pharmacology of learning and memory. Pharmacol Res 50 2 (2004) 111-122
2. Squire L.R. Memory and the hippocampus: a synthesis from findings with rats, monkeys and humans. Psychol Rev 99 (1992) 195-231
3. Fenn K.M., Nusbaum H.C., and Margoliash D. Consolidation during sleep of perceptual learning of spoken language. Nature 425 (2003) 614-616
4. Foster D.J., and Wilson M.A. Reverse replay of behavioural sequences in hippocampal place cells during the awake state. Nature 440 (2006) 680-683
5. Kandel E.R. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep 24 4/5 (2004) 477-522
6. Pascale A., Gusev P.A., Amadio M., Dottorini T., Govoni S., Alkon D.L., et al. Increase of the RNA-binding protein HuD and posttranscriptional up-regulation of the GAP-43 gene during spatial memory. Proc Natl Acad Sci USA 101 5 (2004) 1217-1222
7. Pascale A., Amadio M., Scapagnini G., Lanni C., Racchi M., Provenzani A., et al. Neuronal ELAV proteins enhance mRNA stability by a PKCalpha-dependent pathway. Proc Natl Acad Sci USA 102 34 (2005) 12065-12070
8. Anderson M.C., Ochsner K.N., Kuhl B., Cooper J., Robertson E., Gabrieli S.W., et al. Neural systems underlying the suppression of unwanted memories. Science 303 (2004) 232-235
9. Miller G. Learning to forget. Science 304 (2004) 34-36
10. Bischofberger J. Young and excitable: new neurons in memory networks. Nat Neurosci 10 (2007) 273-275 10.1038/nn0307-273
11. Bruggimann L., Annoni J.M., Staub F., von Steinbüchel N., Van der Linden M., and Bogousslavsky J. Chronic posttraumatic stress symptoms after non severe stroke. Neurology 66 (2006) 513-516
12. Racchi M., Mazzucchelli M., Porrello E., Lanni C., and Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 50 4 (2004) 441-451
13. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 50 4 (2004) 433-440
14. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593
15. Raschetti R., Albanese E., Vanacore N., and Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4 11 (2007) e338
16. Wezenberg E., Verkes R.J., Sabbe B.G., Ruigt G.S., and Hulstijn W. Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. Psychopharmacology 181 3 (2005) 582-594
17. Yesavage J.A., Mumenthaler M.S., Taylor J.L., Friedman L., O'Hara R., Sheikh J., et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 59 (2002) 15-23
18. Beglinger L.J., Tangphao-Daniels O., Kareken D.A., Zhang L., Mohs R., and Siemers E.R. Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. J Clin Psychopharmacol 25 2 (2005) 159-165
19. Lopez C.M., Govoni S., Battaini F., Bergamaschi S., Longoni A., Giaroni C., et al. Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine. Pharmacol Biochem Behav 39 4 (1991) 835-840
20. Sacco K.A., Bannon K.L., and George T.P. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 18 4 (2004) 457-474
21. Davranche K., and Audiffren M. Effects of a low dose of transdermal nicotine on information processing. Nicotine Tob Res 4 3 (2002) 275-285
22. Dunbar G., Boeijinga P.H., Demazières A., Cisterni C., Kuchibhatla R., Wesnes K., et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 191 4 (2007) 919-929
23. http://www.memorypharma.com/pipe.html.
24. http://www.clinicaltrials.gov.
25. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5 (2006) 160-170
26. Coull J.T. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. Drugs Aging 5 2 (1994) 116-126
27. Volkow N.D., Wang G.J., Fowler J.S., Telang F., Maynard L., Logan J., et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 161 7 (2004) 1173-1180
28. Turner D.C., Clark L., Dowson J., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 55 10 (2004) 1031-1040
29. Minzenberg M.J., and Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology (2007) [Epub ahead of print]
30. Stahl S.M. Neurotransmission of cognition. Part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 64 2 (2003) 110-111
31. Tzavara E.T., Bymaster F.P., Overshiner C.D., Davis R.J., Perry K.W., Wolff M., et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 11 (2006) 187-195
32. Sahakian B., and Morein-Zamir S. Professor's little helper. Nature 450 7173 (2007) 1157-1159
33. Baranski J.V., Pigeau R., Dinich P., and Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 19 5 (2004) 323-332
34. Smith A.P. Caffeine at work. Hum Psychopharmacol 20 6 (2005) 441-445
35. Smith A., Brice C., Nash J., Rich N., and Nutt D.J. Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol 17 3 (2003) 283-292
36. Deslandes A.C., Veiga H., Cagy M., Piedade R., Pompeu F., and Ribeiro P. Effects of caffeine on the electrophysiological, cognitive and motor responses of the central nervous system. Braz J Med Biol Res 38 (2005) 1077-1086
37. Govoni S., Petkov V.V., Montefusco O., Missale C., Battaini F., Spano P.F., et al. Differential effects of caffeine on dihydroxyphenylacetic acid concentrations in various rat brain dopaminergic structures. J Pharm Pharmacol 36 7 (1984) 458-460
38. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11 2 (2005) 169-182
39. Bach M.E., Barad M., Son H., Zhuo M., Lu Y.F., Shih R., et al. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci USA 96 9 (1999) 5280-5285
40. Dash P.K., Moore A.N., Kobori N., and Runyan J.D. Molecular activity underlying working memory. Learn Mem 14 8 (2007) 554-563
41. Battaini F., and Mochly-Rosen D. Happy birthday protein kinase C: past, present and future of a superfamily. Pharmacol Res 55 6 (2007) 461-466
42. Pascale A., Amadio M., Govoni S., and Battaini F. The aging brain, a key target for the future: the protein kinase C involvement. Pharmacol Res 55 6 (2007) 560-569
43. Tully T., Bourtchouladze R., Scott R., and Tallman J. Targeting the CREB pathway for memory enhancers. Nat Rev. Drug Discov 2 (2003) 267-277
44. Delfs J.M., Zhu Y., Druhan J.P., and Aston-Jones G.S. Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res 806 2 (1998) 127-140
45. Coull J.T., Frith C.D., Dolan R.J., Frackowiak R.S., and Grasby P.M. The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Eur J Neurosci 9 3 (1997) 589-598
46. Sarter M., Hasselmo M.E., Bruno J.P., and Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and top-down cholinergic modulation of signal detection. Brain Res 48 (2005) 98-111
47. Sarter M., Nelson C.L., and Bruno J.P. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 31 1 (2005) 117-138
48. Sarter M., Gehring W.J., and Kozak R. More attention must be paid: the neurobiology of attentional effort. Brain Res Rev 51 2 (2006) 145-160
49. Perry E., Walker M., Grace J., and Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci 22 6 (1999) 273-280
50. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31 2-3 (2000) 371-384
51. Mesulam M.M. A cortical network for directed attention and unilateral neglect. Ann Neurol 10 4 (1981) 309-325
52. Bellgrove M.A., Chambers C.D., Johnson K.A., Daibhis A., Daly M., Hawi Z., et al. Dopaminergic genotype biases spatial attention in healthy children. Mol Psychiatry 12 8 (2007) 786-792
53. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 9481 (2005) 237-248
54. Bellgrove M.A., Hawi Z., Kirley A., Fitzgerald M., Gill M., and Robertson I.H. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology 30 12 (2005) 2290-2297
55. Wolraich M.L., McGuinn L., and Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 30 1 (2007) 17-26
56. Pliszka S.R. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev 17 1 (2007) 61-72
57. Polzer J., Bangs M.E., Zhang S., Dellva M.A., Tauscher-Wisniewski S., Acharya N., et al. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry 61 5 (2007) 713-719
58. Wang Y., Zheng Y., Du Y., Song D.H., Shin Y.J., Cho S.C., et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust NZ J Psychiatry 41 3 (2007) 222-230
59. Gill M., Haerich P., Westcott K., Godenick K.L., and Tucker J.A. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 13 2 (2006) 158-165
60. Czeisler C.A., Walsh J.K., Roth T., Hughes R.J., Wright K.P., Kingsbury L., et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 353 5 (2005) 476-486
61. Brunnauer A., Laux G., Geiger E., Soyka M., and Möller H.J. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 67 11 (2006) 1776-1781
62. Radhakishun F.S., van den Bos J., van der Heijden B.C., Roes K.C., and O'Hanlon J.F. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20 5 (2000) 531-537
63. Wingen M., Bothmer J., Langer S., and Ramaekers J.G. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 6 4 (2005) 436-443
64. Bora E., Veznedaroǧlu B., and Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 28 3 (2005) 139-141
65. Heller J.H., Spiridigliozzi G.A., Crissman B.G., Sullivan J.A., Eells R.L., Li J.S., et al. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. J Child Adolesc Psychopharmacol 16 6 (2006) 755-765
66. Ferreri F., Agbokou C., and Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 31 6 (2006) 369-376
67. Schubert M.H., Young K.A., and Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60 6 (2006) 530-533
68. Spiridigliozzi G.A., Heller J.H., Crissman B.G., Sullivan-Saarela J.A., Eells R., Dawson D., et al. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med Genet A 143 13 (2007) 1408-1413
69. Rowan E., McKeith I.G., Saxby B.K., O'Brien J.T., Burn D., Mosimann U., et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 23 3 (2007) 161-167
70. Salloway S., Correia S., and Richardson S. Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. Int Psychogeriatr 20 1 (2008) 40-46
71. Findling R.L., McNamara N.K., Stansbrey R.J., Maxhimer R., Periclou A., Mann A., et al. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol 17 1 (2007) 19-33
72. Riepe M.W., Adler G., Ibach B., Weinkauf B., Tracik F., and Gunay I. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord. 23 5 (2007) 301-306
73. Randall D.C., Fleck N.L., Shneerson J.M., and File S.E. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav 77 3 (2004) 547-555
74. Randall D.C., Shneerson J.M., and File S.E. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol Biochem Behav 82 1 (2005) 133-139
75. Milner B., Corkin S., and Teuber H. Further analysis of the hippocampal amnestic syndrome: 14 year follow up-study of HM. Neuropsychologia 6 (1968) 215-234
76. Winocur G. Memory localisation in the brain. In: Squire L.R., and Butters N. (Eds). Neuropsychology of memory (1984), The Guilford Press, New York 122-133
77. Bogen J.E., and Bogen G.M. The other side of the brain. III. The corpus callosum and creativity. Bull Los Angel Neurol Soc 34 (1969) 191-203
78. Hoppe K.D. Hemispheric specialization and creativity. Psychiatr Clin North Am 11 (1988) 303-315
79. Martindale C. The biological basis of creativity. In: Sternberg R.J. (Ed). Handbook of creativity (1999), Cambridge University Press, Cambridge 137-152
80. Dietrich A. The cognitive neuroscience of creativity. Psychon Bull Rev 11 6 (2004) 1011-1026
81. Ashby G.F., Valentin V.V., and Turken A.U. The effects of positive affect and arousal on working memory and executive attention: Neurobiology and computational models. In: Moore S., and Oaksford M. (Eds). Emotional cognition: from brain to behaviour (2002), Benjamins, Amsterdam 245-287
82. Stuss D.T., and Levine B. Adult clinical neuropsychology: lessons from studies of the frontal lobes. Annu Rev Psychol 53 (2002) 401-433
83. Carlsson I., Wendt P.E., and Risberg J. On the neurobiology of creativity Differences in frontal activity between high and low creative subjects. Neuropsychologia 38 (2000) 873-885
84. Snyder A., Bossomaier T., and Mitchell D.J. Concept formation: "object" attributes dynamically inhibited from conscious awareness. J Integr Neurosci 3 (2004) 31-46
85. Gabriels L., Cosyns P., Nuttin B., Demeulemeester H., and Gybels J. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 107 (2003) 275-282
86. Flaherty A.W., Williams Z.M., Rauch S., Cosgrove G.R., and Eskandar E.N. Deep brain stimulation of the anterior internal capsule for treatment of medically refractory Tourette syndrome. J Neurol Neurosurg Psychiatry 57 Suppl. 4 (2005) E403
87. Lombroso C. (ca. 1864) Genio e follia" [Genius and Insanity]. In: Rothenberg A., and Hausman C.R. (Eds). The creative question (1976), Duke University Press, Durham, NC 79-85
88. Sass L.A. Schizophrenia, modernism, and the "creative imagination": on creativity and psychopathology. Creativ Res J 13 (2000) 55-74
89. Rothenberg A. Bipolar illness, creativity, and treatment. Psychiatry Q 72 (2001) 131-147
90. Miller B.L., Cummings J., Mishkin F., Boone K., Prince F., Ponton M., et al. Emergence of artistic talent in frontotemporal dementia. Neurology 51 (1998) 978-982
91. Post F. Creativity psychopathology: a study of 291 world famous men. Br J Psychiatry 165 (1994) 22-34
92. Post F. Verbal creativity, depression and alcoholism: an investigation of one hundred American and British writers. Br J Psychiatry 168 (1996) 545-555
93. Chatterjee A. The neuropsychology of visual artistic production. Neuropsychologia 42 11 (2004) 1568-1583
94. Kleiner-Fisman G., Black S.E., and Lang A.E. Neurodegenerative disease and the evolution of art: the effects of presumed corticobasal degeneration in a professional artist. Mov Disord 18 3 (2003) 294-302
95. Cummings J.L., and Zarit J.M. Probable Alzheimer's disease in an artist. JAMA 258 (1987) 2731-2734
96. Crutch S.J., Isaacs R., and Rossor M.N. Some workmen can blame their tools: artistic change in an individual with Alzheimer's disease. Lancet 357 (2001) 2129-2133
97. Snowden J.S., Neary D., and Mann D.M.A. Fronto-temporal lobar dementia (1996), Churchill-Livingstone, New York, NY pp. 94-7
98. Miller B.L., Ponton M., Benson J.L., Cummings J., and Mena I. Enhanced artistic creativity with temporal lobe degeneration. Lancet 348 (1996) 1744-1745
99. Miller B.L., Boone K., Cummings J., Read S., and Mishkin F. Functional correlates of musical and visual ability in frontotemporal dementia. Br J Psychiatry 176 (2000) 458-463
100. Mell J., Howard S., and Miller B. Art and the brain. The influence of frontotemporal dementia on an accomplished artist. Neurology 60 (2003) 1707-1710
101. Miller B.L., and Hou C.E. Portraits of artists: emergence of visual creativity in dementia. Arch Neurol 61 6 (2004) 842-844
102. Kril J.J., and Halliday G.M. Clinicopathological staging of frontotemporal dementia severity: correlation with regional atrophy. Dement Geriatr Cognit Disord 17 (2004) 311-315
103. Kapur N. Paradoxical functional facilitation in brain-behaviour research: a critical review. Brain 119 Pt 5 (1996) 1775-1790
104. Espinel C.H. de Kooning's late colours and forms: dementia, creativity, and the healing power of art. Lancet 347 (1996) 1096-1098
105. Kirk A., and Kertesz A. On drawing impairment in Alzheimer's disease. Arch Neurol 48 (1991) 73-77
106. Fornazzari L.R. Preserved painting creativity in an artist with Alzheimer's disease. Eur J Neurol 12 6 (2005) 419-424
107. Drago V., Crucian G.P., Foster P.S., Cheong J., Finney G.R., Pisani F., et al. Lewy body dementia and creativity: case report. Neuropsychologia 44 14 (2006) 3011-3015
108. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
109. Mori E. Dementia with lewy bodies. Nippon Ronen Igakkai Zasshi 37 (2000) 772-776
110. Sacks O. Tourette's syndrome and creativity. BMJ 305 6868 (1992) 1515-1516
111. Walker R.H., Warwick R., and Cercy S.P. Augmentation of artistic productivity in Parkinson's disease. Mov Disord 21 2 (2006) 285-286
112. Swerdlow N.R., Stephany N., Wasserman L.C., Talledo J., Sharp R., and Auerbach P.P. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology 169 (2003) 314-320
113. Carson S.H., Peterson J.B., and Higgins D.M. Decreased latent inhibition is associated with increased creative achievement in high-functioning individuals. J Pers Soc Psychol 85 3 (2003) 499-506
114. Keltikangas-Jarvinen L., Elovainio M., Kivimaki M., Lichtermann D., Ekelund J., and Peltonen L. Association between the type 4 dopamine receptor gene polymorphism and novelty seeking. Psychosom Med 65 (2003) 471-476
115. Savitz J.B., and Ramesar R.S. Genetic variants implicated in personality: a review of the more promising candidates. Am J Med Genet B Neuropsychiatr Genet 131 (2004) 20-32
116. Dan N.G. Visual dysfunction in artists. J Clin Neurosci 10 (2003) 168-170
117. Krippner S. Psychedelic drugs and creativity. J Psychoactive Drugs 17 4 (1985) 235-245
118. Janiger O., and Dobkin de Rios M. LSD and creativity. J Psychoactive Drugs 21 1 (1989) 129-134
119. ten Berge J. Jekyll and Hyde revisited: paradoxes in the appreciation of drug experiences and their effects on creativity. J Psychoactive Drugs 34 3 (2002) 249-262
120. Sperry R. Some effects of disconnecting the cerebral hemispheres. Science 217 (1982) 1223-1226
121. Markham J.A., and Greenough W.T. Experience-driven brain plasticity: beyond the synapse. Neuron Glia Biol 1 (2004) 351-363
122. Lindenfors P., Nunn C.L., and Barton R.A. Primate brain architecture and selection in relation to sex. BMC Biol 5 (2007) 20
123. Van Essen D.C., Drury H.A., Dickson J., Harwell J., Hanlon D., and Anderson CH. An integrated software suite for surface-based analyses of cerebral cortex. J Am Med Inform Assoc 8 (2001) 443-459
124. Kötter R. Neuroscience databases: tools for exploring brain structure-function relationships. Philos Trans R Soc Lond B Biol Sci 356 1412 (2001) 1111-1120
125. Chicurel M. Databasing the brain. Nature 406 (2000) 822-825
126. Shepherd G.M., Mirsky J.S., Healy M.D., Singer M.S., Skoufos E., Hines M.S., et al. The human brain project: neuroinformatics tools for integrating, searching and modeling multidisciplinary neuroscience data. Trends Neurosci 21 (1998) 460-468
127. Young M.P., and Scannell J.W. Brain structure-function relationships: advances from neuroinformatics. Philos Trans R Soc Lond B Biol Sci 355 (2000) 3-6
128. Anderson K.E. Dementia in Parkinson's disease. Curr Treat Options Neurol 6 3 (2004) 201-207
129. Mentis M.J., Delalot D., Naqvi H., Gordon M.F., Gudesblatt M., Edwards C., et al. Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease. Mov Disord 21 4 (2006) 549-555
130. Shaw E.G., Rosdhal R., D'Agostino Jr. R.B., Lovato J., Naughton M.J., Robbins M.E., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24 9 (2006) 1415-1420
131. Gebhardt D.O. Off-label administration of drugs to healthy military personnel dubious ethics of preventive measures. J Med Ethics 31 5 (2005) 268
132. Pityaratstian N. Advances in alternative pharmacotherapy of ADHD. J Med Assoc Thai 88 Suppl. 4 (2005) S357-S362
133. Gorus E., Lambert M., De Raedt R., and Mets T. The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. J Clin Psychopharmacol 27 2 (2007) 182-187
134. http://www.targacept.com/wt/page/tc_1734.
135. McShane R., Areosa Sastre A., and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2 (2006) CD003154
136. Charles A., Flippen C., Romero Reyes M., and Brennan K.C. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 8 4 (2007) 248-250
137. Peeters M., Gunthorpe M.J., Strijbos P.J., Goldsmith P., Upton N., and James M.F. Effects of pan- and subtype-selective N-methyl-d-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther 321 2 (2007) 564-572
138. Shorvon S. Pyrrolidone derivatives. Lancet 358 9296 (2001) 1885-1892
139. Wischer S., Paulus W., Sommer M., and Tergau F. Piracetam affects facilitatory I-wave interaction in the human motor cortex. Clin Neurophysiol 112 2 (2001) 275-279
140. Vaglenova J., and Vesselinov Petkov V. Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?. Eur Neuropsychopharmacol 11 1 (2001) 33-40
141. Winnicka K., Tomasiak M., and Bielawska A. Piracetam-an old drug with novel properties?. Acta Pol Pharm 62 5 (2005) 405-409
142. Jelic V., Kivipelto M., and Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 77 4 (2006) 429-438
143. O'Neill M.J., Bleakman D., Zimmerman D.M., and Nisenbaum E.S. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 3 3 (2004) 181-194
144. Gallai V., Mazzotta G., Del Gatto F., Montesi S., Mazzetti A., Dominici P., et al. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline. Acta Neurol (Napoli) 13 1 (1991) 1-12
145. Chorvat R.J., Zaczek R., and Brown B.S. Ion channel modulators that enhance acetylcholine release: potential therapies for Alzheimer' disease. Expert Opin Investig Drugs 7 4 (1998) 499-518
146. http://www.fda.gov.
147. Pataki C.S., Feinberg D.T., and McGough J.J. New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs 9 2 (2004) 293-302
148. Greydanus D.E., Pratt H.D., and Patel D.R. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon 53 2 (2007) 70-131
149. Miller J.L. Modafinil approved for narcolepsy. Am J Health Syst Pharm 56 4 (1999) 304
150. Keating G.M., and Raffin M.J. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs 19 9 (2005) 785-803
151. Caldwell J.A., and Caldwell J.L. Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. Aviat Space Environ Med 76 Suppl. 7 (2005) C39-C51
152. Teitelman E. Off-label uses of modafinil. Am J Psychiatry 158 8 (2001) 1341
153. Dorhout Mees S.M., Rinkel G.J., Feigin V.L., Algra A., van den Bergh W.M., Vermeulen M., et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 3 (2007) CD000277
154. Hausse A.O., Aggoun Y., Bonnet D., Sidi D., Munnich A., Rötig A., et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87 4 (2002) 346-349
155. Romàn G. Perspectives in the treatment of vascular dementia. Drugs Today (Barc) 36 9 (2000) 641-653
156. Ables A.Z., and Baughman III O.L. Antidepressants: update on new agents and indications. Am Fam Physician 67 3 (2003) 547-554
157. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19 6 (2005) 567-596
158. Koran L.M., Gamel N.N., Choung H.W., Smith E.H., and Aboujaoude E.N. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 66 4 (2005) 515-520
159. Asnis G.M., Kohn S.R., Henderson M., and Brown N.L. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 64 4 (2004) 383-404
160. Zanelli S.A., Solenski N.J., Rosenthal R.E., and Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-l-carnitine. Ann NY Acad Sci 1053 (2005) 153-161
161. Wilson A.D., Hart A., Brännström T., Wiberg M., and Terenghi G. Delayed acetyl-l-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury. J Plast Reconstr Aesthet Surg 60 2 (2007) 114-118
162. Salvioli G., and Neri M. l-Acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res 20 4 (1994) 169-176
163. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., et al. Natural antioxidants in Alzheimer' disease. Expert Opin Investig Drugs 16 12 (2007) 1921-1931
164. Parnetti L., Mignini F., Tomassoni D., Traini E., and Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?. J Neurol Sci 257 1-2 (2007) 264-269
165. Kennedy D.O., Jackson P.A., Haskell C.F., and Scholey A.B. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. Hum Psychopharmacol 22 8 (2007) 559-566
166. Elsabagh S., Hartley D.E., Ali O., Williamson E.M., and File S.E. Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers. Psychopharmacology (Berl) 179 2 (2005) 437-446
167. Lovera J., Bagert B., Smoot K., Morris C.D., Frank R., Bogardus K., et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 13 3 (2007) 376-385
168. Chen F., Eckman E.A., and Eckman C.B. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J 20 8 (2006) 1269-1271
169. Fusco D., Colloca G., Lo Monaco M.R., and Cesari M. Effects of antioxidant supplementation on the aging process. Clin Interv Aging 2 3 (2007) 377-387
170. Di Matteo V., and Esposito E. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2 2 (2003) 95-107
171. Clark A.J., Lynch M.E., Ware M., Beaulieu P., McGilveray I.J., and Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 10 Suppl. A (2005) A44-A46
172. Burns T.L., and Ineck J.R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 40 2 (2006) 251-260
173. Blake D.R., Robson P., Ho M., Jubb R.W., and McCabe C.S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45 1 (2006) 50-52
174. Smith P.F. Medicinal cannabis extracts for the treatment of multiple sclerosis. Curr Opin Investig Drugs 5 7 (2004) 727-730
175. Zagnoni P.G., and Albano C. Psychostimulants and epilepsy. Epilepsia 43 Suppl. 2 (2002) 28-31
176. Sewell R.A., Halpern J.H., and Pope Jr. H.G. Response of cluster headache to psilocybin and LSD. Neurology 66 12 (2006) 1920-1922
177. Sessa B. Can psychedelics have a role in psychiatry once again?. Br J Psychiatry 186 (2005) 457-458
178. Langreth R. Viagra for the brain. Forbes Magazine; 2002.
179. Kennedy D. Just treat, or enhance?. Science 304 (2004) 17
180. Rose S.P.R. "Smart Drugs": do they work? Are they ethical? Will they be legal?. Nat Rev Neurosci 3 (2002) 975-979
181. Farah M.J., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P., et al. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 5 (2004) 421-425